Drug
Futuximab clinical trials
Also written Sym004.
- studies test it
- 12
- open now
- 0
- in phase 3
- 2
- first study started
- 2010
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2016 (4)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2016 | 4 |
| 2018 | 1 |
| 2019 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 8
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 2
Symphogen A/S (8) · Annick Desjardins (1) · Merck KGaA, Darmstadt, Germany (1) · Institut de Recherches Internationales Servier (1) · EMD Serono (1)
Often tested with
Tested in the same studies.
Modotuximab (1) · FOLFIRI-Ziv-aflibercept Regimen (1) · FOLFIRI Regimen (1)
Studies
Open first, then newest update. How each study uses futuximab is read from its arms, and is right about nine times in ten.
Testing it · 12
- Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal CancerTerminatedPhase 3Institut de Recherches Internationales ServierNCT05223673Written as Futuximab/modotuximab
- Sym004 Versus Futuximab or Modotuximab in Patients With mCRCTerminatedPhase 2Symphogen A/SNCT03549338Written as Sym004
- Phase 2 Study of Sym004 for Adult Patients With Recurrent GlioblastomaCompletedPhase 2Annick DesjardinsNCT02540161Written as Sym004 - 18 mg/kg
- Sym004 vs Standard of Care in Subjects With Metastatic Colorectal CancerCompletedPhase 2Symphogen A/SNCT02083653Written as Sym004 (12 mg/kg)
- Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer PatientsTerminatedPhase 1/2Symphogen A/SNCT02568046Written as Sym004
- Sym004 Versus TAS-102 in Patients With mCRCWithdrawnPhase 3Symphogen A/SNCT03717038Written as Sym004
- Sym004 in SCCHN Patients Failing Anti-EGFR Based TherapyCompletedPhase 2Symphogen A/SNCT01417936Written as Sym004
- Sym004 in Patients With Advanced Solid TumorsCompletedPhase 1/2Symphogen A/SNCT01117428Written as Sym004
- Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung CancerWithdrawnPhase 1/2Symphogen A/SNCT02924233Written as Sym004
- Japanese Phase 1 Trial of Sym004 in Solid TumorsCompletedPhase 1Merck KGaA, Darmstadt, GermanyNCT01955473Written as Sym004
- Sym004 in Metastatic Colorectal Cancer and ECD-EGFR PatientsWithdrawnPhase 2Symphogen A/SNCT02965417Written as Sym004
- Sym004 in Subjects With Stage IV Non-small Cell Lung CancerTerminatedPhase 1EMD SeronoNCT02083679Written as Part 1: Sym004 6 mg/kg + Cisplatin/Gemcitabine
Codes
What other systems call futuximab · ClinicalTrials.gg INT005966
- MeSH (NLM) C569270futuximabOne source NLM
- UNII (FDA) B37J680LX0FUTUXIMABConfirmed FDA, NLM, Wikidata
- Wikidata Q5510931FutuximabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152971FutuximabOne source FDA
- DrugBank DB15262One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C569270 | futuximab | One source NLM |
| UNII (FDA) | B37J680LX0 | FUTUXIMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q5510931 | Futuximab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152971 | Futuximab | One source FDA |
| DrugBank | DB15262 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.